Tuesday, September 29, 2020
Create an account
REMS in Primary Care
A New Era of Migraine Management: The Changing Landscape of Prevention
The Promise of CGRP Antibodies to Change Practice in Migraine Treatment
Case Studies in Migraine
Clinical Challenges in Migraine: The Role of Emerging Therapies in New Treatment Paradigms
Clinical Dialogues in Pain - OIC
Therapeutic Advances and Evolving Treatment Strategies: Novel Approaches to Migraine Management
Targeting CGRP: Emerging Solutions in Migraine
How to Talk to Your Patients About Opioid-induced Constipation: A Dialogue About New Advances
Patient-Centered Approaches to Treatment of Migraine: Real-World Cases with Real-World Challenges
Friedman Downloadable Slides
Charles Downloadable Slides
Migraine FDA Watch
Knowledge Library - Practice
What are some key counseling points pharmacists should make when talking to patients about opioids?
Kathryn L. Hahn, PharmD, DAAPM, CPE
March 30, 2012
Dr. Hahn discusses what key counseling points a community pharmacist can utilize to allay the fears of potential addiction to their pain patient using chronic opioid therapy.
What is pseudoaddiction?
Bruce D. Nicholson, MD
March 16, 2012
Dr. Nicholson discusses if the undertreatment of pain can result in pseudoaddiction and defines pseudoaddiction.
What key factors should be included in a treatment agreement?
Kenneth L. Kirsh, PhD
February 24, 2012
Dr. Kirsh discusses what key factors should be included in a treatment agreement.
How can I improve communication with a chronic pain patient during a brief follow-up visit?
Daniel B. Carr, MD, FABPM
November 4, 2011
How can we best assess the contributions that community-based pharmacists make to patient outcomes?
Scott Strassels, PharmD, PhD, BCPS
July 29, 2011
Dr. Strassels discusses how we can best assess the contributions that community-based pharmacists make to patient outcomes and if there is data to support this.
Page 3 of 3
Results 21 - 25 of 25